Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. METHODS: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review. RESULTS: The 108 patients with triple-negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression-free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7). CONCLUSIONS: Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall response rate was 33.3% (95% CI 24.6-43.1), with a median duration of response of 7.7 months (95% CI 4.9-10.8).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
In the citing paper
“Of the patients with a response to sacituzumab govitecan-hziy, 55.6% maintained their response for ≥6 months and 16.7% maintained their response for ≥12 months.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationKohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citation
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 · DOI · Paper page
Cited by
Items 301–400 of 874
Bairi, K. E., Jarroudi, O. A., & Afqir, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.031 · Cited by 30
Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
Dey, N., Aske, J. C., & Pradip, D. (2021) · Pharmaceuticals · doi:10.3390/ph14050455 · Cited by 27
Yokota, K., Serada, S., Tsujii, S., Toya, K., Takahashi, T., Matsunaga, T., Fujimoto, M., Uemura, S., Namikawa, T., Murakami, I., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0015 · Cited by 26
Li, S., Bao, C., Huang, L., & Wei, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206021 · Cited by 31
“Moreover, neutropenia was associated with uridine diphosphate glucuronosyltransferase family 1 member A1 (UGT1A1)*28 homozygosity and the incidence increased with the increase in the copy number [52] (Table 2).”
BackgroundAntibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy
Hurwitz, J., Haggstrom, L., & Lim, E. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082017 · Cited by 31
“2020 IMMU-132-01 [74] (phase I/II) Advanced TNBC after ≥2 lines of chemotherapy.”
BackgroundAntibody-Drug Conjugates: Patient and Treatment Selection
Makawita, S., & Meric‐Bernstam, F. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280775 · Cited by 32
Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models
Moquist, P. N., Bovee, T. D., Waight, A. B., Mitchell, J. A., Miyamoto, J. B., Mason, M. L., Emmerton, K. K., Stevens, N. S., Balasubramanian, C., Simmons, J. K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0618 · Cited by 28
Michel, L. S., Jimeno, A., Sukari, A. W., Beck, J. T., Chiu, J. W. Y., Ahern, E. S., Hilton, J. F., Even, C., Zanetta, S., Mekan, S. F., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2523 · Cited by 36
Huang, W., Li, L., Zhou, Y., Yang, Q., Mixdorf, J. C., Barnhart, T. E., Hsu, J. C., Saladin, R. J., Liu, C., Rosenkrans, Z. T., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07106-4 · Cited by 25
“In 2021, Trop2-targeting antibody–drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), demonstrated efficacy in patients with metastatic TNBC [10, 11].”
The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
Guerra, E., & Alberti, S. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-621 · Cited by 29
Kesireddy, M., Kothapalli, S. R., Gundepalli, S. G., & Asif, S. (2023) · Pharmaceutical Medicine · doi:10.1007/s40290-023-00505-8 · Cited by 32
“The FDA initially granted accelerated approval to sacituzumab govitecan for adult patients with metastatic triple-negative breast cancer who received at least 2 prior systemic therapies for metastatic disease based on the IMMU-132-01 study, a single-arm, Phase 1/2 trial [43].”
Emerging treatment approaches for triple-negative breast cancer
Capuozzo, M., Celotto, V., Santorsola, M., Fabozzi, A., Landi, L., Ferrara, F., Borzacchiello, A., Granata, V., Sabbatino, F., Savarese, G., et al. (2023) · Medical Oncology · doi:10.1007/s12032-023-02257-6 · Cited by 29
“Consequently, sacituzumab-govitecan received accelerated approval from the FDA on April 22, 2020, for the treatment of metastatic TNBC patients who have undergone at least two prior treatment regimens [116].”
InfluentialLinehan, A., Fitzpatrick, O. M., & Morris, P. G. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s245024 · Cited by 27
“Sacituzumab govitecan, another antibody–drug conjugate targeting Trop-2 in triple-negative breast cancer showed high rates of neutropenia in a phase II study with 26% of patients experiencing grade ≥3 neutropenia (Figure 1).(26) The most significant and potentially fatal adverse event that was observed with trastuzuma…”
Sultana, R., Chen, S., Lim, E. H., Dent, R. A., & Chowbay, B. (2024) · BJC Reports · doi:10.1038/s44276-024-00106-1 · Cited by 27
Dacoregio, M. I., Michelon, I. F., Castro, C., de Moraes, F. C. A., de Almeida, G. R., Ravani, L. V., Vilbert, M., & Costa, R. L. B. (2024) · The Breast · doi:10.1016/j.breast.2024.103853 · Cited by 28
“Information about preventive measures was available in three studies [8,9,18,21, 22].”
InfluentialAntibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know
Markides, D. M., Hita, A. G., Merlin, J., Reyes-Gibby, C., & Yeung, S. J. (2024) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2024.10.015 · Cited by 27
Breast Cancer: Molecular Pathogenesis and Targeted Therapy
Samad, M. A., Ahmad, I., Khan, M. R., Suhail, M., Zughaibi, T. A., Al-Abbasi, F. A., Alhosaini, K. A., Khan, M. S., Kumer, A., & Tabrez, S. S. M. (2025) · MedComm · doi:10.1002/mco2.70404 · Cited by 34
Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature
Ozaki, Y., Miura, S., Oki, R., Morikawa, T., & Uchino, K. (2021) · Cancers · doi:10.3390/cancers14010196 · Cited by 33
“Sacituzumab govitecan is an ADC consisting of a humanized immunoglobulin IgG1 monoclonal antibody (hRS7) targeting trophoblast cell surface antigen-2 conjugated to SN-38, an active metabolite of irinotecan, which has shown the efficacy in patients with TNBC who received standard chemotherapy [78].”
BackgroundHuo, Y., Shao, S., Liu, E., Li, J., Tian, Z., Wu, X., Zhang, S., Stover, D. G., Wu, H., Cheng, L., et al. (2022) · Cancers · doi:10.3390/cancers14194878 · Cited by 25
“Targeted treatment options are limited for patients whose TNBC becomes resistant to chemotherapy, despite recent FDA approvals of chemo-immunotherapy for cancer that is PDL1+ [6], PARP1 inhibitors olaparib and talazoparib for patients with BRAC1/2 mutations [7–9], and antibody-drug conjugates for late-line therapy [10…”
BackgroundMethodSun, M., Chen, G., Ouyang, S., Chen, C., Zheng, Z., Lin, P., Song, X., Chen, H., Chen, Y., You, Y., et al. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c00307 · Cited by 24
Opportunities and obstacles of targeted therapy and immunotherapy in small cell lung cancer
Lin, Y., Lai, Q., Gou, L., Feng, J., & Yang, J. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1797050 · Cited by 26
Xu, X., Yu, T., & Wang, Z. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103012 · Cited by 27
Huynh, M.-M., Pambid, M. R., Jayanthan, A., Dorr, A., Los, G., & Dunn, S. E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1818067 · Cited by 25
Establishment of a novel anti-TROP2 monoclonal antibody TrMab-29 for immunohistochemical analysis
Sayama, Y., Kaneko, M. K., Takei, J., Hosono, H., Sano, M., Asano, T., & Kato, Y. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100902 · Cited by 23
Michaleas, S., Oliver, A. M., Mueller-Berghaus, J., Sarac, S. B., van der Elst, M. E., Müller-Egert, S., Zander, H., Enzmann, H., & Pignatti, F. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100497 · Cited by 25
Sacituzumab govitecan in triple-negative breast cancer
de Nonneville, A. T., Gonçalvès, A., Mamessier, É., & Bertucci, F. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-813 · Cited by 24
“Promising results from a small study led on April 2020 to the accelerated approval of SG in patients with advanced TNBC (5).”
BackgroundZhu, J., Wu, W., Togashi, Y., Nihira, N. T., Johmura, Y., Zhu, D., Nakanishi, M., Miyoshi, Y., & Ohta, T. (2022) · Breast Cancer · doi:10.1007/s12282-022-01389-3 · Cited by 23
Nguyen, H.-M., Paulishak, W., Oladejo, M., & Wood, L. M. (2022) · Breast Cancer · doi:10.1007/s12282-022-01415-4 · Cited by 25
“3% of patients in the treatment group showed complete or partial tumor regression [104].”
BackgroundEgelston, C. A., Guo, W., Yost, S. E., Ge, X., Lee, J. S., Frankel, P. H., Cui, Y., Ruel, C., Schmolze, D. D., Murga, M., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03470-y · Cited by 27
“Recent US Food and Drug Administration (FDA) approvals in TNBC, namely PARP inhibitors for BRCA germline-mutated tumors [2, 3], immune checkpoint inhibitors (ICIs) for programmed deathligand 1 (PD-L1) positive TNBC [4], and antibody drug conjugate targeting the Trop-2 receptor [5] have changed the landscape of mTNBC t…”
BackgroundGuidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)
Xu, B., & Ma, F. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.12.001 · Cited by 30
Zheng, C., Liu, Y., Wang, X., Bi, Z., Qiu, P., Qiao, G., Bi, X., Shi, Z., Zhang, Z., Chen, P., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000001011 · Cited by 24
“Triple-negative breast cancer (TNBC) is associated with aggressive tumor biology and a dismal prognosis, approximately accounting for 15% of invasive breast cancers [1] .”
BackgroundPedersini, R., Buffoni, M., Petrelli, F., Ghidini, A., di Mauro, P., Amoroso, V., Parati, M. C., Laini, L., Cosentini, D., Schivardi, G., et al. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.04.003 · Cited by 23
Trop-2 expression and the tumor immune microenvironment in cervical cancer
Chiba, Y., Kojima, Y., Yazaki, S., Yoshida, H., Takamizawa, S., Kitadai, R., Saito, A., Okuma, H. S., Nishikawa, T., Shimoi, T., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.04.022 · Cited by 26
Jakabová, A., Bielčiková, Z., Pospíšilová, E., Petruzelka, L. B., Błasiak, P., Bobek, V., & Kološtová, K. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211028492 · Cited by 25
Wang, H., Bai, H., Wang, J., Zhou, X., Chen, H., Wang, L., Ren, H., Liu, Z., Zhuo, W., Zhou, Z., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121458 · Cited by 25
Condic, M., EGGER, E. K., Klümper, N., Kristiansen, G., Mustea, A., Thiesler, T., & Ralser, D. J. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04761-8 · Cited by 22
“SG has recently been approved for the treatment of metastatic triplenegative breast cancer and is considered for further indications with plethora of clinical trials ongoing (Bardia et al. 2019).”
BackgroundThe Relationship between Trop-2, Chemotherapeutic Drugs, and Chemoresistance
Koltai, T., & Fliegel, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010087 · Cited by 23
“Patients should have previously received treatment based on endocrine therapy and would have had at least two additional systemic therapies in the advanced stage [94,95].”
MethodSacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
Rossi, V., Turati, A., Rosato, A., & Carpanese, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447280 · Cited by 25
Novel treatment approaches utilizing antibody-drug conjugates in breast cancer
Davis, A. A., Hesse, J., Pereira, P. M. R., & Ma, C. X. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00743-w · Cited by 31
Perrotti, V., Caponio, V. C. A., Mascitti, M., Muzio, L. L., Piattelli, A., Rubini, C., Capone, E., & Sala, G. (2021) · Cancers · doi:10.3390/cancers13133126 · Cited by 22
Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers
Si, Y., Chen, K., Ngo, H. G., Guan, J. S., Totoro, A., Zhou, Z. “., Kim, S., Kim, T. H., Zhou, L., & Liu, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010146 · Cited by 23
Yong, W. P., Teo, F. S. W., Teo, L., Ng, M. C. H., Tan, T. J., Low, S. Y., Wong, K., Ang, P., Choo, S. P., Lee, K. H., et al. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2162383 · Cited by 22
Trop-2 is a ubiquitous and promising target in pancreatic adenocarcinoma
Mas, L., Cros, J. F., Svrcek, M., Laethem, J. V., Emile, J., Rebours, V., Nicolle, R., & Bachet, J. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102108 · Cited by 23
Advances in PET/CT Imaging for Breast Cancer
de Jong, D., Desperito, E., Feghali, K. A. A., Dercle, L., Seban, R., Das, J. P., Ma, H., Sajan, A., Braumuller, B., Prendergast, C. M., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134537 · Cited by 22
“New therapeutic molecules, antibody-drug conjugates (for example sacituzumab-govitecan) [71,72], and combined therapy regimens (for example, chemoimmunotherapy) [73,74] have revolutionized the management of breast cancer, particularly in patients whose prognosis is the worst among breast cancer types.”
BackgroundNicolini, A., & Ferrari, P. (2024) · Cancers · doi:10.3390/cancers16020466 · Cited by 24
“…(SN-38) [44], has been shown to increase objective response rates (ORRs) and median PFS in heavily pretreated HR+/HER2 − or metastatic triple-negative breast cancer (TNBC) patients, compared to conventional chemotherapy (33.3% and 5.5 months vs. 10–15% and 2–3 months, respectively) [44,52–54].”
BackgroundInfluentialTan, A. C., Boggs, D. H., Lee, E. Q., Kim, M. M., Mehta, M. P., & Khasraw, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780379 · Cited by 23
“Notably this included small cell lung cancer (SCLC) with Study B-005 (lurbinectedin) (16), EGFR mutated non-small cell lung cancer (NSCLC) with ARCHER 1050 (dacomitinib) (17) and triple negative breast cancer (TNBC) with IMMU-132-01 (sacituzumab govitecan) (18).”
BackgroundModern developments in germline pharmacogenomics for oncology prescribing
Reizine, N. M., & O’Donnell, P. H. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21722 · Cited by 31
Racial disparities in breast cancer preclinical and clinical models
Clarke, S., Chin, S. N., Dodds, L. V., George, S. H. L., & Badal, S. A. M. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01551-x · Cited by 23
Barve, M. A., Aaron, P. A., Manning, L., Bognar, E., Wallraven, G., Horvath, S., Stanbery, L., & Nemunaitis, J. J. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221110501 · Cited by 22
Švec, J., Šťastná, M., Janečková, L., Hrčkulák, D., Vojtěchová, M., Onhajzer, J., Kříž, V., Galušková, K., Šloncová, E., Kubovčiak, J., et al. (2022) · Cancers · doi:10.3390/cancers14174137 · Cited by 23
“Food and Drug Administration (FDA) for the third-line treatment of patients with metastatic triplenegative breast cancer (TNBC) and urothelial carcinoma [30,31].”
BackgroundA review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm
Roy, A. M., Kumarasamy, V. M., Dhakal, A., O'Regan, R. M., & Gandhi, S. (2023) · Cancer · doi:10.1002/cncr.34904 · Cited by 25
“5 months and 13 months, respectively, in patients with heavily pretreated metastatic TNBC.(34) Later, in the randomized, phase 3 ASCENT trial, SG was found to have a significant PFS and OS benefit compared with single‐agent PCC among patients with metastatic TNBC.”
BackgroundInfluentialWang, Y., Gao, B., Zhang, L., Wang, X., Zhu, X., Yang, H., Zhang, F., Zhu, X., Zhou, B., Yao, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-024-45693-2 · Cited by 21
“A negative control to show that a protein does not bind to the R-loop is required.”
Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer
Nagahashi, M., & Miyoshi, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063354 · Cited by 23
Vorobyeva, A., Bezverkhniaia, E., Коновалова, Е. В., Schulga, A. A., Garousi, J., Vorontsova, O. V., Abouzayed, A., Orlova, A., Deyev, S. M., & Максимилианович, Т. В. (2020) · Molecules · doi:10.3390/molecules25204719 · Cited by 22
“It showed a 33% response rate in patients with metastatic TNBC pretreated with chemotherapy [7].”
BackgroundA Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer
Mo, H., Jazieh, K., Brinzevich, D., & Abraham, J. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.05.014 · Cited by 23
Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy
Foldi, J., Rozenblit, M., Park, T. S., Knowlton, C. A., Golshan, M. A., Moran, M. S., & Pusztai, L. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00879-4 · Cited by 21
Li, W.-F., Chiang, M.-F., Weng, H.-C., Yang, J.-J., Wu, H., Wu, S., Chen, Y.-J., Lu, C., Tu, J.-S., Hsu, R.-Y., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0588 · Cited by 22
Ebrahim, N. A. A., Hussein, M. A., Sobeih, M. E., & Amin, N. H. (2025) · BMC Cancer · doi:10.1186/s12885-025-14402-7 · Cited by 20
Omori, S., Muramatsu, K., Kawata, T., Miyawaki, E., Miyawaki, T., Mamesaya, N., Kawamura, T., Kobayashi, H., Nakashima, K., Wakuda, K., et al. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03784-3 · Cited by 27
Lim, B., Peterson, C. B., Davis, A., Cho, E., Pearson, T., Liu, H., Hwang, M., Ueno, N. T., & Lee, J. (2021) · Biomedicines · doi:10.3390/biomedicines9101410 · Cited by 26
“Although new targeted therapeutics, such as sacituzumab govitecan-hziy (anti-TROP2 antibody-drug conjugate) [1] and immunotherapeutics, have been effective against triplenegative breast cancer (TNBC) [2], patients still suffer from therapy resistance and disease progression.”
BackgroundNicolini, A., Ferrari, P., & Carpi, A. (2022) · Biomedicines · doi:10.3390/biomedicines10102511 · Cited by 20
Knowledge atlas of antibody-drug conjugates on CiteSpace and clinical trial visualization analysis
Yao, P., Zhang, Y., Zhang, S., Wei, X., Liu, Y., Du, C., Hu, M., Feng, C., Li, J., Zhao, F., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1039882 · Cited by 22
“At present, the most commonly used non-cleavable linker is a succinimide-thioether bond, which is usually coupled with maytansinoid derivatives DM1 and auristatin (17).”
BackgroundThe ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review
Filis, P., Zerdes, I., Soumala, T., Matikas, A., & Foukakis, T. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104189 · Cited by 21
Precision targeting in oncology: The future of conjugated drugs
Li, J., Liu, L., & Zhao, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117106 · Cited by 23
Huang, W., Zhang, Y., Xiao, X., Yang, Q., Mixdorf, J. C., Sun, X., Engle, J. W., Fan, Y., Li, L., Kang, L., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07167-5 · Cited by 21
“In 2021, the Trop2-targeting antibody–drug conjugate (ADC) sacituzumab govitecan (Tro-delvy™) demonstrated remarkable efficacy in patients with metastatic triple-negative breast cancer [ 7, 8].”
Shome, R., & Ghosh, S. S. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00296 · Cited by 20
Novitasari, D., Jenie, R. I., Wulandari, F., Utomo, R. Y., Putri, D. D. P., Kato, J., & Meiyanto, E. (2021) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2021.00760 · Cited by 23
Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
Ryu, W., & Sohn, J. (2021) · Pharmaceuticals · doi:10.3390/ph14101008 · Cited by 23
“Following accelerated approval based on results of a phase II clinical trial, the randomized phase III ASCENT (NCT01631552) trial showed longer PFS with sacituzumab govitecan than with standard chemotherapy, leading to approval of the new ADC for refractory metastatic TNBC [94].”
MethodCurrent and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer
Pauls, M., Chia, S., & LeVasseur, N. (2022) · Current Oncology · doi:10.3390/curroncol29070377 · Cited by 21
“SN-38, an active metabolite of irinotecan, reversibly binds the topoisomerase 1 cleavage complex on DNA and interrupts DNA replication in cancer cells, causing S-phase-specific cell death [18].”
BackgroundEnhancing radiotherapy techniques for Triple-Negative breast cancer treatment
Sarlak, S., Pagès, G., & Luciano, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102939 · Cited by 19
“Histopathological BC subtypes. conjugates (ADC) such as trastuzumab emtansine and trastuzumab deruxtecan for HER2-positive cancers and sacituzumab govitecan (Trodelvy) for metastatic TNBC [11 – 13].”
HER2-Low Breast Cancer—Current Knowledge and Future Directions
Shaaban, A. M., Kaur, T., & Provenzano, E. (2025) · Medicina · doi:10.3390/medicina61040644 · Cited by 19
“…or SG should be considered, while HER2-ultralow tumours should be treated with SG followed by other lines of There are several other HER2-based ADCs in pre-clinical or early-phase clinical trials, including agents designed to target HER2-low breast cancers [26]. other lines of chemotherapy [32,33].”
Lan, J., Nie, W., Bi, Z., Zeng, R., Li, Z., Zhang, T., & Ding, Y. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03708-0 · Cited by 19
Major clinical research advances in gynecologic cancer in 2019
Kim, M., Suh, D. H., Lee, K.-H., Eom, K., Lee, J., Lee, Y.-Y., Hansen, H. F., Mirza, M. R., & Kim, J. (2020) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2020.31.e48 · Cited by 19
“Radiation oncology Inferiority of NAC plus CRT to CRT alone [40] Treatment of radiation-induced cystitis with hyperbaric oxygen [42] Breast Humanized monoclonal antibodies in breast cancer [43,44] Combination therapy in breast cancer [45,47,51]”
Finding the positive in triple-negative breast cancer
Carey, L. (2021) · Nature Cancer · doi:10.1038/s43018-021-00211-x · Cited by 21
Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer
Fertal, S. A., Poterala, J. E., Ponik, S. M., & Wisinski, K. B. (2022) · Cancers · doi:10.3390/cancers14051238 · Cited by 21
3D-Informed Targeting of the Trop-2 Signal-Activation Site Drives Selective Cancer Vulnerability
Guerra, E., Trerotola, M., Relli, V., Lattanzio, R., Tripaldi, R., Ceci, M., Boujnah, K., Pantalone, L., Sacchetti, A., Havas, K. M., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0352 · Cited by 20
Li, X., Zhang, L., Hu, S., Liu, D., Hu, B., Ran, J., Lin, X., Mao, W., & Hu, J. Y. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3098 · Cited by 20
“4,19 It could be inferred that sacituzumab govitecan might instigate serious AEs that are yet to be identified.”
BackgroundDermatologic toxicities of antibody-drug conjugates
Gronbeck, C., Hadfield, M. J., & Grant-Kels, J. M. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.08.036 · Cited by 20
Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
Fang, H., Cavaliere, A., Li, Z., Huang, Y. H., & Marquez-Nostra, B. V. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.627693 · Cited by 20
Blondeaux, E., Boni, L., Chilà, G., Dri, A., Caputo, R., Poggio, F. B., Fabi, A., Arpino, G., Pravisano, F., Geuna, E., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104125 · Cited by 21
Metastatic Triple-Negative Breast Cancer
Zhang, X., & Yeung, K. T. (2023) · Current Breast Cancer Reports · doi:10.1007/s12609-023-00493-3 · Cited by 18
Shi, J., Jiao, T., Guo, Q., Weng, W., Ma, L., Zhang, Q., Wang, L., Zhang, J., Chen, C., Huang, Y., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1356 · Cited by 20
Li, J., Shen, G., Liu, Z., Liu, Y., Wang, M., Zhao, F., Ren, D., Xie, Q., Li, Z., Liu, Z., et al. (2023) · Cancer Innovation · doi:10.1002/cai2.97 · Cited by 21
Sun, C., Yang, X., Tang, L., & Chen, J. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2277801 · Cited by 21
“[25].”
ImmunoPET Imaging of Trop2 Expression in Bladder Cancer Using [64Cu]Cu-NOTA-Trodelvy
Huang, W., Wang, T., Chao, F., Yang, Q. E., Mixdorf, J. C., Li, L., Engle, J. W., Fan, Y., Kang, L., & Cai, W. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00069 · Cited by 18
Progress in systemic therapy for triple-negative breast cancer
Mo, H., & Xu, B. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0741-5 · Cited by 19
Recent updates in systemic therapy of breast cancer: A brief narrative review
Arora, S., & Gogia, A. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_335_20 · Cited by 19
Reuss, J. E., Gosa, L., & Liu, S. V. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.07.011 · Cited by 19
The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon
Ahmed, Y., Berenguer-Pina, J. J., & Mahgoub, T. (2021) · Oncology · doi:10.1159/000517438 · Cited by 18
Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
Jeong, J. H., & Kim, S. (2022) · The Breast · doi:10.1016/j.breast.2022.10.015 · Cited by 19
“NeoSTAR was a phase II trial evaluating neoadjuvant SG for patients with localized TNBC (tumor size ≥1 cm or any size if node-positive) (Fig.”
BackgroundInfluentialZhou, M., Huang, Z., Ma, Z., Chen, J., Lin, S., Yang, X., Gong, Q., Braunstein, Z., Wei, Y., Rao, X., et al. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.49 · Cited by 43
Millul, J., Krudewig, C., Zana, A., Plaza, S. D., Puca, E., Villa, A., Neri, D., & Cazzamalli, S. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0361 · Cited by 18
Montero, J. C., Calvo-Jiménez, E., del Carmen, S., Abad, M., Ocaña, A., & Pandiella, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02330-4 · Cited by 22
Kong, C., Pu, J., Zhao, Q., Weng, W., Ma, L., Qian, Y., Hu, W., Meng, X., & Meng, T. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0164 · Cited by 17
Neuroendocrine neoplasms of the breast: a review of literature
Vegni, F., Stefano, I. S. D., Policardo, F., Tralongo, P., Feraco, A., Carlino, A., Ferraro, G., Zhang, Q., Scaglione, G., D’Alessandris, N., et al. (2024) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-024-03856-y · Cited by 19
Sathe, A. G., Diderichsen, P. M., Fauchet, F., Phan, S., Girish, S., & Othman, A. A. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3495 · Cited by 18
Novel targeted therapies for metastatic breast cancer
Jazieh, K., Bell, R., Agarwal, N., & Abraham, J. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.03.43 · Cited by 20
“When studied in phase I/II trials of patients with metastatic TNBC who had undergone prior treatments (65,66), sacituzumab govitecan resulted in around a 30% response rate and”
MethodCurrent and emerging biologic therapies for triple negative breast cancer
Shaikh, S. S., & Emens, L. A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1801627 · Cited by 19
Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative
Vidula, N., Ellisen, L. W., & Bardia, A. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7600 · Cited by 19
Self-citationXu, X., Zhang, J., Zhang, Z., Wang, M., Liu, Y., & Li, X. (2020) · Bioengineered · doi:10.1080/21655979.2020.1834726 · Cited by 18
Metadata
- Authors
- Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., Shah, N. C., Rugo, H. S., Goldenberg, D. M., Sweidan, A. M., Iannone, R., Washkowitz, S., Sharkey, R. M., Wegener, W. A., & Kalinsky, K.
- Affiliations
- Harvard University (US)
- Vanderbilt University (US)
- Cornell University (US)
- Orlando Health (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 741-751
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2917403028
- Cited by
- 874
- References
- 37
- Citations by year
- 2026: 76 · 2025: 103 · 2024: 111 · 2023: 125 · 2022: 167 · 2021: 167 · 2020: 91 · 2019: 32
- FWCI
- 36.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Immunomedics Inc
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- sacituzumab govitecan, antibody-drug conjugates, metastatic triple-negative breast cancer, TROP2, SN-38, refractory disease, objective response rate, duration of response, progression-free survival, overall survival, safety, febrile neutropenia, anemia, neutropenia
- MeSH terms
- Irinotecan, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anemia, Antigens, Neoplasm, Antineoplastic Agents, Camptothecin, Diarrhea, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Cell Adhesion Molecules, Survival Rate, Immunoconjugates, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.